loncastuximab tesirine 后 CAR-T 细胞治疗大 B 细胞淋巴瘤的真实世界治疗：通俗语言摘要

What is this summary about? This summary describes an article published in the medical journal eJHaem in September 2024. The article reports a real-world study in which the authors looked at how therapies worked in everyday settings by using the Center for International Blood and Marrow Transplant Research or CIBMTR Database to collect information on individuals with diffuse large B-cell lymphoma or DLBCL .

The study included 16 adults with DLBCL in the United States who had accepted 2 therapies that target different regions of the same protein, which is called CD19, on cancer cells. All individuals received loncastuximab tesirine, known as Lonca, before receiving CAR-T therapy . The authors studied how both therapies worked in all individuals and in 2 smaller Lonca groups: one group who was given Lonca as bridging therapy and another group who received Lonca as the last cancer therapy before CAR-T therapy. What were the results?

Overall, 10 of 16 (63%) individuals with DLBCL who received Lonca before CAR-T therapy had their cancer either completely disappear or get smaller after therapy. This happened in the overall group and the 2 smaller Lonca groups, who received Lonca as a bridging therapy or as the last therapy before CAR-T therapy.

Investigators estimated that 1 year after CAR-T therapy, 33% of individuals would still be alive, and 28% would be alive without their disease worsening. What do the results mean? Treating individuals with Lonca does not stop individuals from responding to CAR-T therapy in the future. The authors think that this may be possible because the therapies target different regions of the CD19 protein on the cancer cell surface. [Box: see text].